Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24549561 | 0.79 | ALDH1A1 (0.36) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL30437196 | 0.78 | KMT2A (0.40) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL24549560 | 0.76 | KMT2A (0.39) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL2643051 | 0.72 | HPGD (0.42) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL24549368 | 0.72 | ALDH1A1 (0.51) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL9095713 | 0.71 | ALOX5AP (0.34) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL429397 | 0.71 | HPGD (0.38) | ALDH1A1KMT2AMEN1LMNAMAPT | |
| SCHEMBL23531858 | 0.71 | HPGD (0.38) | ALDH1A1KMT2AMEN1SMN1; SMN2MAPT | |
| SCHEMBL23170681 | 0.71 | HPGD (0.38) | ALDH1A1KMT2AMEN1SMN1; SMN2LMNA | |
| SCHEMBL2642538 | 0.69 | ALDH1A1 (0.41) | ALDH1A1KMT2AMEN1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | Optikira, LLC | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220194945-A1 | Imidazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN2, ERN1 | ALDH1A1 2541/4885KMT2A 3370/4885MEN1 3778/4885 |
| US-20220153734-A1 | Pyrazolopyridine Compounds For IRE1 Inhibition | XBP1, ERN1, ERN2 | ALDH1A1 2438/4885KMT2A 3650/4885MEN1 3912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.